It is known that the CV protection effect of GLP-1RAs have been proven through eight large-scale clinical studies, including Evaluation of LIXisenatide in Acute coronary syndrome (ELIXA) [66], LEADER [44], Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes (SUSTAIN)-6 [67], Exenatide Study of Cardiovascular Event Lowering (EXSCEL) [68], Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes) [69], Researching Cardiovascular Events with a Weekly INcretin in Diabetes (REWIND) [70], Peptide Innovation for Early Diabetes Treatment (PIONEER) 6 [67,71], and AMPLITUDE-O [51]
Nausea or Dizziness Nausea or dizziness can occur shortly after injection
& Hahn, E.G
Discuss your personal risk profile with your surgeon
Lpez-Otn C, Blasco MA, Partridge L, Serrano M, Kroemer G
Uric acid, lung function, physical capacity and exacerbation frequency in patients with COPD: a multi-dimensional approach